Frankfurt
26.06.26 | 08:04
53,00 Euro
-1,85 % -1,00
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 53,50 | 55,00 | 26.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 39 | GlobeNewswire (USA) | ||
| 05.05. | Novozymes A/S reports Q1 results | 47 | Seeking Alpha | ||
| 05.05. | Novonesis Q1 2026 slides: 7% organic growth amid currency headwinds | 36 | Investing.com | ||
| 05.05. | Novonesis Q1 2026: Organisches Wachstum von 7 % trotz Währungsgegenwind | 24 | Investing.com Deutsch | ||
| 05.05. | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | 637 | AFX News | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| 05.05. | Novonesis (Novozymes A/S): Interim report Q1 2026 | 685 | GlobeNewswire (Europe) | Strong start to the year with 7% organic sales growth and 37.8% adjusted EBITDA margin Ester Baiget, President & CEO:" The year started strong with 7% organic sales growth against a high comparable.... ► Artikel lesen | |
| 08.04. | Novonesis To Acquire Thailand Production Facility For Around $50 Mln | 660 | AFX News | WASHINGTON (dpa-AFX) - Novozymes A/S, Novonesis (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B), a biotechnology company, on Wednesday announced an agreement to acquire a production facility... ► Artikel lesen | |
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 08.04. | Novonesis (Novozymes A/S): Novonesis expands global footprint with acquisition of production facility in Southeast Asia | 628 | GlobeNewswire (Europe) | Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company's long-term... ► Artikel lesen | |
| 25.03. | Dividendenbekanntmachungen (25.03.2026) | 8.074 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AFYA LIMITED KYG011251066 0,656 USD 0,5648 EUR ALTRIA GROUP INC US02209S1033 1,06 USD 0,9127 EUR ATLAS ARTERIA AU0000013559 0... ► Artikel lesen | |
| 23.03. | Novonesis (Novozymes A/S): Resolutions from the Annual General Meeting 2026 | 2.274 | GlobeNewswire (Europe) | Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit... ► Artikel lesen | |
| 23.03. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 11 | GlobeNewswire (USA) | ||
| 23.03. | Novonesis & Hewlett Packard Enterprise Dividenden im global market - Ex-Tag 24.03.2026 | 41 | Wiener Börse | ||
| 16.03. | Novonesis (Novozymes A/S): Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility | 762 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors.
The transaction was primarily undertaken... ► Artikel lesen | |
| 13.03. | Novonesis (Novozymes A/S): Novonesis issues EUR 1.7 billion senior unsecured notes | 519 | GlobeNewswire (Europe) | On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed... ► Artikel lesen | |
| 11.03. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 23 | GlobeNewswire (USA) | ||
| 09.03. | Novonesis named a Great Employer to Work For in North Carolina | 17 | GlobeNewswire (USA) | ||
| 26.02. | Novonesis (Novozymes A/S): Invitation to the 2026 Annual General Meeting | 7 | GlobeNewswire (USA) | ||
| 26.02. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 5 | GlobeNewswire (USA) | ||
| 26.02. | Novozymes Reports Climb In Q4 Bottom Line | 760 | AFX News | BRUSSELS (dpa-AFX) - Novozymes (NVZMF.PK) reported earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings came in at EUR122.8 million, or EUR1.25... ► Artikel lesen | |
| 25.02. | Novozymes A/S Non-GAAP EPS of €1.49, revenue of €4.16B | 18 | Seeking Alpha |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,300 | -0,30 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| GENMAB | 226,50 | -0,96 % | Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,660 | -1,08 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 0,931 | +1,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| BASILEA | 55,90 | -0,36 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 70,92 | +2,13 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 9,184 | -0,68 % | Why this top investor is snapping up millions of Telix shares | ||
| TWIST BIOSCIENCE | 85,42 | -2,53 % | LenioBio GmbH: LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery | LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,460 | -2,23 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| REPLIGEN | 127,50 | -1,24 % | Repligen Corporation (RGEN) Dropped Following the Earnings Release | ||
| REVOLUTION MEDICINES | 160,00 | +0,03 % | Revolution Medicines, Inc.: Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic ... | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced... ► Artikel lesen |
Das Unternehmen NOVONESIS A/S ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,85 % bei einem Aktienkurs von 53,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.